Progress in tumor-associated macrophage (TAM)-targeted therapeutics

Advanced Drug Delivery Reviews

Volumn 114, Issue , 2017, Pages 206-221

  Ngambenjawong, Chayanon ^a   Gustafson, Heather H ^a   Pun, Suzie H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer immunotherapy; Drug delivery; Targeted therapy; Tumor microenvironment; Tumor associated macrophage

Indexed keywords

CELL PROLIFERATION; DISEASES; DRUG DELIVERY; MACROPHAGES; TARGETED DRUG DELIVERY; TISSUE HOMEOSTASIS; TUMORS;

ANGIOGENESIS; CANCER IMMUNOTHERAPY; HIGH PLASTICITY; INNATE IMMUNES; TARGETED THERAPEUTICS; TARGETED THERAPY; TUMOR ASSOCIATED MACROPHAGES; TUMOR MICROENVIRONMENT;

DIAGNOSIS;

ALKYLATING AGENT; AMINO ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CD47 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1 RECEPTOR; DRUG CARRIER; EPIDERMAL GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; GPR132 PROTEIN; GROWTH FACTOR; LACTIC ACID; LIPID; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RON PROTEIN; SCAVENGER RECEPTOR; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN;

AMINO ACID METABOLISM; ANGIOGENESIS; CARCINOGENESIS; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; LIPID METABOLISM; MACROPHAGE; MALIGNANT NEOPLASM; MONONUCLEAR PHAGOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PROCEDURES; VASCULARIZATION;

ANIMALS; HUMANS; IMMUNOTHERAPY; MACROPHAGES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85018922906     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2017.04.010     Document Type: Review

References (227)

1. Hume, D.A., The mononuclear phagocyte system. Curr. Opin. Immunol. 18 (2006), 49–53, 10.1016/j.coi.2005.11.008.
2. Mass, E., Ballesteros, I., Farlik, M., Halbritter, F., Gunther, P., Crozet, L., et al. Specification of tissue-resident macrophages during organogenesis. Science, 353, 2016, 10.1126/science.aaf4238.
3. Schulz, C., Gomez Perdiguero, E., Chorro, L., Szabo-Rogers, H., Cagnard, N., Kierdorf, K., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336 (2012), 86–90, 10.1126/science.1219179.
4. Wynn, T.A., Chawla, A., Pollard, J.W., Macrophage biology in development, homeostasis and disease. Nature 496 (2013), 445–455, 10.1038/nature12034.
5. Ginhoux, F., Jung, S., Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14 (2014), 392–404, 10.1038/nri3671.
6. Lewis, C.E., Harney, A.S., Pollard, J.W., The multifaceted role of perivascular macrophages in tumors. Cancer Cell, 30, 2016, 365, 10.1016/j.ccell.2016.07.009.
7. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., Allavena, P., Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol., 2017, 10.1038/nrclinonc.2016.217.
8. Mechnikov, I.I., Immunity in infective diseases. Rev. Infect. Dis. 10 (1988), 223–227, 10.1093/clinids/10.1.223.
9. Paolicelli, R.C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333 (2011), 1456–1458, 10.1126/science.1202529.
10. Nayak, D., Roth, T.L., McGavern, D.B., Microglia development and function. Annu. Rev. Immunol. 32 (2014), 367–402, 10.1146/annurev-immunol-032713-120240.
11. Ganz, T., Macrophages and systemic iron homeostasis. J. Innate Immun. 4 (2012), 446–453, 10.1159/000336423.
12. Hvidberg, V., Maniecki, M.B., Jacobsen, C., Hojrup, P., Moller, H.J., Moestrup, S.K., Identification of the receptor scavenging hemopexin-heme complexes. Blood 106 (2005), 2572–2579, 10.1182/blood-2005-03-1185.
13. Kohyama, M., Ise, W., Edelson, B.T., Wilker, P.R., Hildner, K., Mejia, C., et al. Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature 457 (2009), 318–321, 10.1038/nature07472.
14. Merad, M., Manz, M.G., Karsunky, H., Wagers, A., Peters, W., Charo, I., et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3 (2002), 1135–1141, 10.1038/ni852.
15. Hussell, T., Bell, T.J., Alveolar macrophages: plasticity in a tissue-specific context. Nat. Rev. Immunol. 14 (2014), 81–93, 10.1038/nri3600.
16. Stockand, J.D., Sansom, S.C., Glomerular mesangial cells: electrophysiology and regulation of contraction. Physiol. Rev. 78 (1998), 723–744.
17. Ajami, B., Bennett, J.L., Krieger, C., McNagny, K.M., Rossi, F.M.V., Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14 (2011), 1142–1149, 10.1038/nn.2887.
18. Brown, M.B., von Chamier, M., Allam, A.B., Reyes, L., M1/M2 macrophage polarity in normal and complicated pregnancy. Front. Immunol., 5, 2014, 606, 10.3389/fimmu.2014.00606.
19. Renaud, S.J., Graham, C.H., The role of macrophages in utero-placental interactions during normal and pathological pregnancy. Immunol. Investig. 37 (2008), 535–564, 10.1080/08820130802191375.
20. Davies, L.C., Jenkins, S.J., Allen, J.E., Taylor, P.R., Tissue-resident macrophages. Nat. Immunol. 14 (2013), 986–995, 10.1038/ni.2705.
21. Lavin, Y., Mortha, A., Rahman, A., Merad, M., Regulation of macrophage development and function in peripheral tissues. Nat. Rev. Immunol. 15 (2015), 731–744, 10.1038/nri3920.
22. Lavin, Y., Winter, D., Blecher-Gonen, R., David, E., Keren-Shaul, H., Merad, M., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159 (2014), 1312–1326, 10.1016/j.cell.2014.11.018.
23. Okabe, Y., Medzhitov, R., Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157 (2014), 832–844, 10.1016/j.cell.2014.04.016.
24. Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11 (2010), 373–384, 10.1038/ni.1863.
25. Takeda, K., Akira, S., TLR signaling pathways. Semin. Immunol. 16 (2004), 3–9.
26. Malyshev, I., Malyshev, Y., Current concept and update of the macrophage plasticity concept: intracellular mechanisms of reprogramming and M3 macrophage “switch” phenotype. Biomed. Res. Int., 2015, 2015, 341308, 10.1155/2015/341308.
27. Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., et al. Essential role of Stat6 in IL-4 signalling. Nature 380 (1996), 627–630, 10.1038/380627a0.
28. Gordon, S., Martinez, F.O., Alternative activation of macrophages: mechanism and functions. Immunity 32 (2010), 593–604, 10.1016/j.immuni.2010.05.007.
29. Martinez, F.O., Helming, L., Gordon, S., Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27 (2009), 451–483, 10.1146/annurev.immunol.021908.132532.
30. Van Dyken, S.J., Locksley, R.M., Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu. Rev. Immunol. 31 (2013), 317–343, 10.1146/annurev-immunol-032712-095906.
31. Italiani, P., Boraschi, D., From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front. Immunol., 5, 2014, 514, 10.3389/fimmu.2014.00514.
32. Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20, 10.1016/j.immuni.2014.06.008.
33. Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep., 6, 2014, 13, 10.12703/P6-13.
34. Zhou, D., Huang, C., Lin, Z., Zhan, S., Kong, L., Fang, C., et al. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell. Signal. 26 (2014), 192–197, 10.1016/j.cellsig.2013.11.004.
35. Elinav, E., Nowarski, R., Thaiss, C.A., Hu, B., Jin, C., Flavell, R.A., Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13 (2013), 759–771, 10.1038/nrc3611.
36. Evans, R., Alexander, P., Cooperation of immune lymphoid cells with macrophages in tumour immunity. Nature 228 (1970), 620–622.
37. Wang, H.-W., Joyce, J.A., Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle 9 (2010), 4824–4835, 10.4161/cc.9.24.14322.
38. Quail, D.F., Joyce, J.A., Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19 (2013), 1423–1437, 10.1038/nm.3394.
39. Caux, C., Ramos, R.N., Prendergast, G.C., Bendriss-Vermare, N., Ménétrier-Caux, C., A milestone review on how macrophages affect tumor growth. Cancer Res., 76, 2016 (6439 LP-6442. http://cancerres.aacrjournals.org/content/76/22/6439.abstract).
40. Ostuni, R., Kratochvill, F., Murray, P.J., Natoli, G., Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 36 (2017), 229–239, 10.1016/j.it.2015.02.004.
41. Quail, D.F., Joyce, J.A., Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies. Clin. Cancer Res., 2016 (http://clincancerres.aacrjournals.org/content/early/2016/11/24/1078-0432.CCR-16-0133.abstract).
42. Yuan, Z.-Y., Luo, R.-Z., Peng, R.-J., Wang, S.-S., Xue, C., High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco. Targets Ther. 7 (2014), 1475–1480, 10.2147/OTT.S61838.
43. Ruffell, B., Affara, N.I., Coussens, L.M., Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33 (2012), 119–126, 10.1016/j.it.2011.12.001.
44. Ma, J., Liu, L., Che, G., Yu, N., Dai, F., You, Z., The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer, 10, 2010, 112, 10.1186/1471-2407-10-112.
45. Mei, J., Xiao, Z., Guo, C., Pu, Q., Ma, L., Liu, C., et al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: a systemic review and meta-analysis. Oncotarget 7 (2016), 34217–34228, 10.18632/oncotarget.9079.
46. Gu, L., Li, H., Chen, L., Ma, X., Li, X., Gao, Y., et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget 7 (2016), 31926–31942, 10.18632/oncotarget.7876.
47. Drake, M.T., Clarke, B.L., Khosla, S., Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83 (2008), 1032–1045 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667901/).
48. Roelofs, A.J., Thompson, K., Gordon, S., Rogers, M.J., Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12 (2006), 6222s–6230s, 10.1158/1078–0432.CCR-06-0843.
49. Junankar, S., Shay, G., Jurczyluk, J., Ali, N., Down, J., Pocock, N., et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov. 5 (2015), 35–42, 10.1158/2159-8290.CD-14-0621.
50. Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell. Mol. Med. 14 (2010), 2803–2815, 10.1111/j.1582-4934.2009.00926.x.
51. Zeisberger, S.M., Odermatt, B., Marty, C., Zehnder-Fjallman, A.H.M., Ballmer-Hofer, K., Schwendener, R.A., Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95 (2006), 272–281, 10.1038/sj.bjc.6603240.
52. Rogers, T.L., Holen, I., Tumour macrophages as potential targets of bisphosphonates. J. Transl. Med., 9, 2011, 177, 10.1186/1479-5876-9-177.
53. Zhang, W., Zhu, X.-D., Sun, H.-C., Xiong, Y.-Q., Zhuang, P.-Y., Xu, H.-X., et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16 (2010), 3420–3430, 10.1158/1078-0432.CCR-09-2904.
54. Hattori, Y., Shibuya, K., Kojima, K., Miatmoko, A., Kawano, K., Ozaki, K.-I., et al. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin. Int. J. Oncol. 47 (2015), 211–219, 10.3892/ijo.2015.2991.
55. Ohara, Y., Oda, T., Yamada, K., Hashimoto, S., Akashi, Y., Miyamoto, R., et al. Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells. Int. J. Cancer 131 (2012), 2402–2410, 10.1002/ijc.27502.
56. Moynihan, K.D., Opel, C.F., Szeto, G.L., Tzeng, A., Zhu, E.F., Engreitz, J.M., et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22 (2016), 1402–1410, 10.1038/nm.4200.
57. Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142 (2010), 699–713, 10.1016/j.cell.2010.07.044.
58. Lehmann, B., Biburger, M., Brückner, C., Ipsen-Escobedo, A., Gordan, S., Lehmann, C., et al. Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. Sci. Immunol., 2, 2017 (http://immunology.sciencemag.org/content/2/7/eaah6413.abstract).
59. Pucci, F., Garris, C., Lai, C.P., Newton, A., Pfirschke, C., Engblom, C., et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352 (2016), 242–246, 10.1126/science.aaf1328.
60. Ohnishi, K., Komohara, Y., Saito, Y., Miyamoto, Y., Watanabe, M., Baba, H., et al. CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci. 104 (2013), 1237–1244, 10.1111/cas.12212.
61. Shiota, T., Miyasato, Y., Ohnishi, K., Yamamoto-Ibusuki, M., Yamamoto, Y., Iwase, H., et al. The clinical significance of CD169-positive lymph node macrophage in patients with breast cancer. PLoS One, 11, 2016, e0166680 (http://dx.doi.org/10.1371%2Fjournal.pone.0166680).
62. Michaelson, M.D., Smith, M.R., Bisphosphonates for treatment and prevention of bone metastases. J. Clin. Oncol. 23 (2005), 8219–8224, 10.1200/JCO.2005.02.9579.
63. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468832.htm.
64. Otero, K., Turnbull, I.R., Poliani, P.L., Vermi, W., Cerutti, E., Aoshi, T., et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat. Immunol. 10 (2009), 734–743, 10.1038/ni.1744.
65. Lin, H., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320 (2008), 807–811, 10.1126/science.1154370.
66. Hume, D.A., MacDonald, K.P.A., Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119 (2012), 1810–1820, 10.1182/blood-2011-09-379214.
67. Lohela, M., Casbon, A.-J., Olow, A., Bonham, L., Branstetter, D., Weng, N., et al. Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E5086–E5095, 10.1073/pnas.1419899111.
68. Fend, L., Accart, N., Kintz, J., Cochin, S., Reymann, C., Le Pogam, F., et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS One, 8, 2013, e73310, 10.1371/journal.pone.0073310.
69. MacDonald, K.P.A., Palmer, J.S., Cronau, S., Seppanen, E., Olver, S., Raffelt, N.C., et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116 (2010), 3955–3963, 10.1182/blood-2010-02-266296.
70. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19 (2013), 1264–1272, 10.1038/nm.3337.
71. Strachan, D.C., Ruffell, B., Oei, Y., Bissell, M.J., Coussens, L.M., Pryer, N., et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 + T cells. Oncoimmunology, 2, 2013, e26968, 10.4161/onci.26968.
72. Quail, D.F., Bowman, R.L., Akkari, L., Quick, M.L., Schuhmacher, A.J., Huse, J.T., et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science, 352, 2016, aad3018, 10.1126/science.aad3018.
73. Jeong, W., Doroshow, J.H., Kummar, S., US FDA approved oral kinase inhibitors for the treatment of malignancies. Curr. Probl. Cancer 37 (2013), 110–144, 10.1016/j.currproblcancer.2013.06.001.
74. Broekman, F., Giovannetti, E., Peters, G.J., Tyrosine kinase inhibitors: multi-targeted or single-targeted?. World J. Clin. Oncol. 2 (2011), 80–93, 10.5306/wjco.v2.i2.80.
75. Kogan, M., Fischer-Smith, T., Kaminsky, R., Lehmicke, G., Rappaport, J., CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines. Anticancer Res. 32 (2012), 893–899 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601026/).
76. Brownlow, N., Russell, A.E., Saravanapavan, H., Wiesmann, M., Murray, J.M., Manley, P.W., et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 22 (2007), 649–652, 10.1038/sj.leu.2404944.
77. Brownlow, N., Mol, C., Hayford, C., Ghaem-Maghami, S., Dibb, N.J., Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 23 (2008), 590–594, 10.1038/leu.2008.237.
78. Tap, W.D., Wainberg, Z.A., Anthony, S.P., Ibrahim, P.N., Zhang, C., Healey, J.H., et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N. Engl. J. Med. 373 (2015), 428–437, 10.1056/NEJMoa1411366.
79. Chaudhuri, A., Regulation of macrophage polarization by RON receptor tyrosine kinase signaling. Front. Immunol., 5, 2014, 546, 10.3389/fimmu.2014.00546.
80. Lutz, M.A., Correll, P.H., Activation of CR3-mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3-kinase, and protein kinase C zeta. J. Leukoc. Biol. 73 (2003), 802–814.
81. Sharda, D.R., Yu, S., Ray, M., Squadrito, M.L., De Palma, M., Wynn, T.A., et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J. Immunol. 187 (2011), 2181–2192, 10.4049/jimmunol.1003460.
82. Morrison, A.C., Wilson, C.B., Ray, M., Correll, P.H., Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J. Immunol. 172 (2004), 1825–1832.
83. Chen, Y.Q., Fisher, J.H., Wang, M.H., Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J. Immunol. 161 (1998), 4950–4959.
84. Gurusamy, D., Gray, J.K., Pathrose, P., Kulkarni, R.M., Finkleman, F.D., Waltz, S.E., Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. Cancer Res. 73 (2013), 1752–1763, 10.1158/0008-5472.CAN-12-2474.
85. Eyob, H., Ekiz, H.A., DeRose, Y.S., Waltz, S.E., Williams, M.A., Welm, A.L., Inhibition of Ron kinase blocks conversion of micrometastases to overt metastases by boosting anti-tumor immunity. Cancer Discov. 3 (2013), 751–760, 10.1158/2159-8290.CD-12-0480.
86. Bieniasz, M., Radhakrishnan, P., Faham, N., De La O, J.-P., Welm, A.L., Preclinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon-expressing breast cancer patient-derived xenografts. Clin. Cancer Res. 21 (2015), 5588–5600, 10.1158/1078–0432.CCR-14-3283.
87. Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 11 (2012), 317–328, 10.1158/1535-7163.MCT-11-0474.
88. Lavin, Y., Merad, M., Macrophages: gatekeepers of tissue integrity. Cancer Immunol. Res. 1 (2013), 201–209, 10.1158/2326-6066.CIR-13-0117.
89. Gul, N., van Egmond, M., Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 75 (2015), 5008–5013, 10.1158/0008–5472.CAN-15-1330.
90. Tipton, T.R.W., Roghanian, A., Oldham, R.J., Carter, M.J., Cox, K.L., Mockridge, C.I., et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood 125 (2015), 1901–1909, 10.1182/blood-2014-07-588376.
91. Shi, Y., Fan, X., Deng, H., Brezski, R.J., Rycyzyn, M., Jordan, R.E., et al. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcgamma receptors on macrophages. J. Immunol. 194 (2015), 4379–4386, 10.4049/jimmunol.1402891.
92. Grugan, K.D., McCabe, F.L., Kinder, M., Greenplate, A.R., Harman, B.C., Ekert, J.E., et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J. Immunol. 189 (2012), 5457–5466, 10.4049/jimmunol.1201889.
93. Taylor, R.P., Lindorfer, M.A., Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol. Pharmacol. 86 (2014), 485–491, 10.1124/mol.114.092684.
94. Velmurugan, R., Challa, D.K., Ram, S., Ober, R.J., Ward, E.S., Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells. Mol. Cancer Ther. 15 (2016), 1879–1889, 10.1158/1535–7163.MCT-15-0335.
95. Richards, J.O., Karki, S., Lazar, G.A., Chen, H., Dang, W., Desjarlais, J.R., Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7 (2008), 2517–2527, 10.1158/1535-7163.MCT-08-0201.
96. Brandsma, A.M., Ten Broeke, T., Nederend, M., Meulenbroek, L.A.P.M., van Tetering, G., Meyer, S., et al. Simultaneous targeting of FcgammaRs and FcalphaRI enhances tumor cell killing. Cancer Immunol. Res. 3 (2015), 1316–1324, 10.1158/2326–6066.CIR-15-0099-T.
97. Josephs, D.H., Bax, H.J., Dodev, T., Georgouli, M., Nakamura, M., Pellizzari, G., et al. Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors via TNF-α/MCP-1 signaling. Cancer Res., 2017 (http://cancerres.aacrjournals.org/content/early/2017/01/14/0008-5472.CAN-16-1829.abstract).
98. Willingham, S.B., Volkmer, J.-P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 6662–6667, 10.1073/pnas.1121623109.
99. Weiskopf, K., Ring, A.M., Ho, C.C.M., Volkmer, J.-P., Levin, A.M., Volkmer, A.K., et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341 (2013), 88–91, 10.1126/science.1238856.
100. Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One, 10, 2015, e0137345, 10.1371/journal.pone.0137345.
101. Ho, C.C.M., Guo, N., Sockolosky, J.T., Ring, A.M., Weiskopf, K., Ozkan, E., et al. “Velcro” engineering of high affinity CD47 ectodomain as signal regulatory protein alpha (SIRPalpha) antagonists that enhance antibody-dependent cellular phagocytosis. J. Biol. Chem. 290 (2015), 12650–12663, 10.1074/jbc.M115.648220.
102. Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol. Ther., 2017, 10.1016/j.ymthe.2016.11.006.
103. Weiskopf, K., Anderson, K.L., Ito, D., Schnorr, P.J., Tomiyasu, H., Ring, A.M., et al. Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20. Cancer Immunol. Res. 4 (2016), 1072–1087, 10.1158/2326-6066.CIR-16-0105.
104. Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., et al. The cellular and molecular origin of tumor-associated macrophages. Science 344 (2014), 921–925, 10.1126/science.1252510.
105. Sanford, D.E., Belt, B.A., Panni, R.Z., Mayer, A., Deshpande, A.D., Carpenter, D., et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin. Cancer Res. 19 (2013), 3404–3415, 10.1158/1078-0432.CCR-13-0525.
106. Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 11 (2012), 812–824, 10.1016/j.stem.2012.08.013.
107. Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475 (2011), 222–225, 10.1038/nature10138.
108. Engblom, C., Pfirschke, C., Pittet, M.J., The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16 (2016), 447–462, 10.1038/nrc.2016.54.
109. Ji, J., Eggert, T., Budhu, A., Forgues, M., Takai, A., Dang, H., et al. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology 62 (2015), 481–495, 10.1002/hep.27822.
110. Lim, S.Y., Yuzhalin, A.E., Gordon-Weeks, A.N., Muschel, R.J., Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7 (2016), 28697–28710, 10.18632/oncotarget.7376.
111. Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K.D., Varga, Z., Junt, T., et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515 (2014), 130–133, 10.1038/nature13862.
112. Kirk, P.S., Koreckij, T., Nguyen, H.M., Brown, L.G., Snyder, L.A., Vessella, R.L., et al. Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. Int. J. Mol. Sci. 14 (2013), 10483–10496, 10.3390/ijms140510483.
113. Hughes, R., Qian, B.-Z., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O.C., et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 75 (2015), 3479–3491, 10.1158/0008-5472.CAN-14-3587.
114. Wang, S.-C., Yu, C.-F., Hong, J.-H., Tsai, C.-S., Chiang, C.-S., Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. PLoS One, 8, 2013, e69182, 10.1371/journal.pone.0069182.
115. Sanchez-Martin, L., Estecha, A., Samaniego, R., Sanchez-Ramon, S., Vega, M.A., Sanchez-Mateos, P., The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117 (2011), 88–97, 10.1182/blood-2009-12-258186.
116. Vonderheide, R.H., Glennie, M.J., Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19 (2013), 1035–1043, 10.1158/1078–0432.CCR-12-2064.
117. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331 (2011), 1612–1616, 10.1126/science.1198443.
118. Long, K.B., Gladney, W.L., Tooker, G.M., Graham, K., Fraietta, J.A., Beatty, G.L., IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 6 (2016), 400–413, 10.1158/2159-8290.CD-15-1032.
119. Li, F., Ravetch, J.V., Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333 (2011), 1030–1034, 10.1126/science.1206954.
120. White, A.L., Chan, H.T.C., Roghanian, A., French, R.R., Mockridge, C.I., Tutt, A.L., et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187 (2011), 1754–1763, 10.4049/jimmunol.1101135.
121. Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19 (2011), 512–526, 10.1016/j.ccr.2011.02.005.
122. Coffelt, S.B., Tal, A.O., Scholz, A., De Palma, M., Patel, S., Urbich, C., et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 70 (2010), 5270–5280, 10.1158/0008-5472.CAN-10-0012.
123. Coutelle, O., Schiffmann, L.M., Liwschitz, M., Brunold, M., Goede, V., Hallek, M., et al. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours. Br. J. Cancer 112 (2015), 495–503, 10.1038/bjc.2014.629.
124. Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 4476–4481, 10.1073/pnas.1525360113.
125. Jassar, A.S., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M.B., Cheung, L., et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8 + T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 65 (2005), 11752–11761, 10.1158/0008-5472.CAN-05-1658.
126. Ghesquiere, B., Wong, B.W., Kuchnio, A., Carmeliet, P., Metabolism of stromal and immune cells in health and disease. Nature 511 (2014), 167–176, 10.1038/nature13312.
127. Weichhart, T., Hengstschlager, M., Linke, M., Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15 (2015), 599–614, 10.1038/nri3901.
128. Rodrik-Outmezguine, V.S., Okaniwa, M., Yao, Z., Novotny, C.J., McWhirter, C., Banaji, A., et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534 (2016), 272–276, 10.1038/nature17963.
129. Chen, W., Ma, T., Shen, X., Xia, X., Xu, G., Bai, X., et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 72 (2012), 1363–1372, 10.1158/0008-5472.CAN-11-2684.
130. Kaneda, M.M., Messer, K.S., Ralainirina, N., Li, H., Leem, C.J., Gorjestani, S., et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539 (2016), 437–442, 10.1038/nature19834.
131. Arranz, A., Doxaki, C., Vergadi, E., Martinez de la Torre, Y., Vaporidi, K., Lagoudaki, E.D., et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 9517–9522, 10.1073/pnas.1119038109.
132. Sahin, E., Haubenwallner, S., Kuttke, M., Kollmann, I., Halfmann, A., Dohnal, A.M., et al. Macrophage PTEN regulates expression and secretion of arginase I modulating innate and adaptive immune responses. J. Immunol. 193 (2014), 1717–1727, 10.4049/jimmunol.1302167.
133. Colegio, O.R., Chu, N.-Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563, 10.1038/nature13490.
134. Chen, P., Zuo, H., Xiong, H., Kolar, M.J., Chu, Q., Saghatelian, A., et al. Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 580–585, 10.1073/pnas.1614035114.
135. Cheng, W.Y., Huynh, H., Chen, P., Pena-Llopis, S., Wan, Y., Macrophage PPARgamma inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. elife, 5, 2016, 10.7554/eLife.18501.
136. Kusmartsev, S., Gabrilovich, D.I., STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174 (2005), 4880–4891.
137. Munn, D.H., Shafizadeh, E., Attwood, J.T., Bondarev, I., Pashine, A., Mellor, A.L., Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189 (1999), 1363–1372.
138. Beloribi-Djefaflia, S., Vasseur, S., Guillaumond, F., Lipid metabolic reprogramming in cancer cells. Oncogene, 5, 2016, e189, 10.1038/oncsis.2015.49.
139. Prima, V., Kaliberova, L.N., Kaliberov, S., Curiel, D.T., Kusmartsev, S., COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proc. Natl. Acad. Sci. U. S. A., 2017, 10.1073/pnas.1612920114.
140. Jung, M., Oren, B., Mora, J., Mertens, C., Dziumbla, S., Popp, R., et al. Lipocalin 2 from macrophages stimulated by tumor cell-derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis. Sci. Signal., 9, 2016, ra64, 10.1126/scisignal.aaf3241.
141. Nakanishi, Y., Nakatsuji, M., Seno, H., Ishizu, S., Akitake-Kawano, R., Kanda, K., et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 32 (2011), 1333–1339, 10.1093/carcin/bgr128.
142. Torti, S.V., Torti, F.M., Ironing out cancer. Cancer Res. 71 (2011), 1511–1514, 10.1158/0008–5472.CAN-10-3614.
143. Torti, S.V., Torti, F.M., Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13 (2013), 342–355, 10.1038/nrc3495.
144. Mertens, C., Akam, E.A., Rehwald, C., Brüne, B., Tomat, E., Jung, M., Intracellular iron chelation modulates the macrophage iron phenotype with consequences on tumor progression. PLoS One, 11, 2016, e0166164 (http://dx.doi.org/10.1371%2Fjournal.pone.0166164).
145. Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11 (2016), 986–994, 10.1038/nnano.2016.168.
146. Bruns, H., Buttner, M., Fabri, M., Mougiakakos, D., Bittenbring, J.T., Hoffmann, M.H., et al. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma. Sci. Transl. Med., 7, 2015, 282ra47, 10.1126/scitranslmed.aaa3230.
147. Canton, J., Neculai, D., Grinstein, S., Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 13 (2013), 621–634, 10.1038/nri3515.
148. Yu, X., Guo, C., Fisher, P.B., Subjeck, J.R., Wang, X.-Y., Scavenger receptors: emerging roles in cancer biology and immunology. Adv. Cancer Res. 128 (2015), 309–364, 10.1016/bs.acr.2015.04.004.
149. Georgoudaki, A.-M., Prokopec, K.E., Boura, V.F., Hellqvist, E., Sohn, S., Ostling, J., et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 15 (2016), 2000–2011, 10.1016/j.celrep.2016.04.084.
150. Neyen, C., Plüddemann, A., Mukhopadhyay, S., Maniati, E., Bossard, M., Gordon, S., et al. Macrophage scavenger receptor a promotes tumour progression in murine models of ovarian and pancreatic cancer. J. Immunol. 190 (2013), 3798–3805, 10.4049/jimmunol.1203194.
151. Neyen, C., Mukhopadhyay, S., Gordon, S., Hagemann, T., An apolipoprotein A-I mimetic targets scavenger receptor a on tumor-associated macrophages: a prospective anticancer treatment?. Oncoimmunology., 2, 2013, e24461, 10.4161/onci.24461.
152. Zhang, H., Zhang, W., Sun, X., Dang, R., Zhou, R., Bai, H., et al. Class A1 scavenger receptor modulates glioma progression by regulating M2-like tumor-associated macrophage polarization. Oncotarget 7 (2016), 50099–50116, 10.18632/oncotarget.10318.
153. Cespedes, M.V., Guillen, M.J., Lopez-Casas, P.P., Sarno, F., Gallardo, A., Alamo, P., et al. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. Dis. Model. Mech. 9 (2016), 1461–1471, 10.1242/dmm.026369.
154. Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23 (2013), 249–262, 10.1016/j.ccr.2013.01.008.
155. Liguori, M., Buracchi, C., Pasqualini, F., Bergomas, F., Pesce, S., Sironi, M., et al. Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment. Oncotarget 7 (2016), 41662–41676, 10.18632/oncotarget.9340.
156. Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65 (2005), 2964–2971, 10.1158/0008-5472.CAN-04-4037.
157. Mantovani, A., Allavena, P., The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212 (2015), 435–445, 10.1084/jem.20150295.
158. De Palma, M., Lewis, C.E., Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23 (2013), 277–286, 10.1016/j.ccr.2013.02.013.
159. Mullins, D.W., Burger, C.J., Elgert, K.D., Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J. Immunol. 162 (1999), 6811–6818.
160. Kodumudi, K.N., Woan, K., Gilvary, D.L., Sahakian, E., Wei, S., Djeu, J.Y., A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16 (2010), 4583–4594, 10.1158/1078-0432.CCR-10-0733.
161. Guerriero, J.L., Ditsworth, D., Catanzaro, J.M., Sabino, G., Furie, M.B., Kew, R.R., et al. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J. Immunol. 186 (2011), 3517–3526, 10.4049/jimmunol.1003267.
162. Bryniarski, K., Szczepanik, M., Ptak, M., Zemelka, M., Ptak, W., Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol. Rep. 61 (2009), 550–557.
163. Baghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, N., Putra, W.E., et al. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res. 76 (2016), 6030–6042, 10.1158/0008–5472.CAN-16-1170.
164. Kaczanowska, S., Joseph, A.M., Davila, E., TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 93 (2013), 847–863, 10.1189/jlb.1012501.
165. Tang, X., Mo, C., Wang, Y., Wei, D., Xiao, H., Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 138 (2013), 93–104, 10.1111/imm.12023.
166. Gebremeskel, S., Johnston, B., Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget 6 (2015), 41600–41619 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747176/).
167. Zheng, J.H., Nguyen, V.H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S.H., et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci. Transl. Med., 9, 2017 (http://stm.sciencemag.org/content/9/376/eaak9537.abstract).
168. Hagemann, T., Lawrence, T., McNeish, I., Charles, K.A., Kulbe, H., Thompson, R.G., et al. “Re-educating” tumor-associated macrophages by targeting NF-κB. J. Exp. Med., 205, 2008 (1261 LP-1268. http://jem.rupress.org/content/205/6/1261.abstract).
169. Tabata, Y., Ikada, Y., Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9 (1988), 356–362.
170. Champion, J.A., Mitragotri, S., Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 4930–4934, 10.1073/pnas.0600997103.
171. He, C., Hu, Y., Yin, L., Tang, C., Yin, C., Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31 (2010), 3657–3666, 10.1016/j.biomaterials.2010.01.065.
172. Sosale, N.G., Spinler, K.R., Alvey, C., Discher, D.E., Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific “Marker of Self” CD47, and target physical properties. Curr. Opin. Immunol. 35 (2015), 107–112, 10.1016/j.coi.2015.06.013.
173. Chono, S., Tanino, T., Seki, T., Morimoto, K., Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J. Pharm. Pharmacol. 59 (2007), 75–80, 10.1211/jpp.59.1.0010.
174. Chang, Y.-N., Guo, H., Li, J., Song, Y., Zhang, M., Jin, J., et al. Adjusting the balance between effective loading and vector migration of macrophage vehicles to deliver nanoparticles. PLoS One, 8, 2013, e76024, 10.1371/journal.pone.0076024.
175. Clift, M.J.D., Rothen-Rutishauser, B., Brown, D.M., Duffin, R., Donaldson, K., Proudfoot, L., et al. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol. Appl. Pharmacol. 232 (2008), 418–427, 10.1016/j.taap.2008.06.009.
176. Schwendener, R.A., Lagocki, P.A., Rahman, Y.E., The effects of charge and size on the interaction of unilamellar liposomes with macrophages. Biochim. Biophys. Acta 772 (1984), 93–101.
177. Yu, S.S., Lau, C.M., Thomas, S.N., Jerome, W.G., Maron, D.J., Dickerson, J.H., et al. Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int. J. Nanomedicine 7 (2012), 799–813, 10.2147/IJN.S28531.
178. Herd, H., Daum, N., Jones, A.T., Huwer, H., Ghandehari, H., Lehr, C.-M., Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano 7 (2013), 1961–1973, 10.1021/nn304439f.
179. Allen, T.M., Austin, G.A., Chonn, A., Lin, L., Lee, K.C., Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim. Biophys. Acta 1061 (1991), 56–64.
180. Key, J., Palange, A.L., Gentile, F., Aryal, S., Stigliano, C., Di Mascolo, D., et al. Soft discoidal polymeric nanoconstructs resist macrophage uptake and enhance vascular targeting in tumors. ACS Nano 9 (2015), 11628–11641, 10.1021/acsnano.5b04866.
181. Li, Z., Sun, L., Zhang, Y., Dove, A.P., O'Reilly, R.K., Chen, G., Shape effect of Glyco-nanoparticles on macrophage cellular uptake and immune response. ACS Macro Lett. 5 (2016), 1059–1064, 10.1021/acsmacrolett.6b00419.
182. Qiu, Y., Liu, Y., Wang, L., Xu, L., Bai, R., Ji, Y., et al. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. Biomaterials 31 (2010), 7606–7619, 10.1016/j.biomaterials.2010.06.051.
183. Bartneck, M., Keul, H.A., Singh, S., Czaja, K., Bornemann, J., Bockstaller, M., et al. Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano 4 (2010), 3073–3086, 10.1021/nn100262h.
184. MacParland, S.A., Tsoi, K.M., Ouyang, B., Ma, X.-Z., Manuel, J., Fawaz, A., et al. Phenotype determines nanoparticle uptake by human macrophages from liver and blood. ACS Nano 11 (2017), 2428–2443, 10.1021/acsnano.6b06245.
185. Blanco, E., Shen, H., Ferrari, M., Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33 (2015), 941–951, 10.1038/nbt.3330.
186. Tsai, C.-Y., Lu, S.-L., Hu, C.-W., Yeh, C.-S., Lee, G.-B., Lei, H.-Y., Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J. Immunol. 188 (2012), 68–76, 10.4049/jimmunol.1100344.
187. Herd, H.L., Bartlett, K.T., Gustafson, J.A., McGill, L.D., Ghandehari, H., Macrophage silica nanoparticle response is phenotypically dependent. Biomaterials 53 (2015), 574–582, 10.1016/j.biomaterials.2015.02.070.
188. Tanei, T., Leonard, F., Liu, X., Alexander, J.F., Saito, Y., Ferrari, M., et al. Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases. Cancer Res. 76 (2016), 429–439, 10.1158/0008-5472.CAN-15-1576.
189. Van Rooijen, N., Sanders, A., Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174 (1994), 83–93.
190. Zhu, S., Niu, M., O'Mary, H., Cui, Z., Targeting of tumor-associated macrophages made possible by PEG-Sheddable, mannose-modified nanoparticles. Mol. Pharm. 10 (2013), 3525–3530, 10.1021/mp400216r.
191. Sun, X., Gao, D., Gao, L., Zhang, C., Yu, X., Jia, B., et al. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer. Theranostics 5 (2015), 597–608, 10.7150/thno.11546.
192. Irache, J.M., Salman, H.H., Gamazo, C., Espuelas, S., Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5 (2008), 703–724, 10.1517/17425247.5.6.703.
193. Hattori, Y., Yamashita, J., Sakaida, C., Kawano, K., Yonemochi, E., Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages. J. Liposome Res. 25 (2015), 131–140, 10.3109/08982104.2014.954128.
194. Puig-Kroger, A., Sierra-Filardi, E., Dominguez-Soto, A., Samaniego, R., Corcuera, M.T., Gomez-Aguado, F., et al. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69 (2009), 9395–9403, 10.1158/0008-5472.CAN-09-2050.
195. Golani, L.K., Wallace-Povirk, A., Deis, S.M., Wong, J., Ke, J., Gu, X., et al. Tumor targeting with novel 6-substituted Pyrrolo [2,3-d] pyrimidine antifolates with heteroatom bridge substitutions via cellular uptake by folate receptor α and the proton-coupled folate transporter and inhibition of de novo purine nucleotide biosynthesis. J. Med. Chem. 59 (2016), 7856–7876, 10.1021/acs.jmedchem.6b00594.
196. Nagai, T., Tanaka, M., Tsuneyoshi, Y., Xu, B., Michie, S.A., Hasui, K., et al. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol. Immunother. 58 (2009), 1577–1586, 10.1007/s00262-009-0667-x.
197. Xia, W., Hilgenbrink, A.R., Matteson, E.L., Lockwood, M.B., Cheng, J.-X., Low, P.S., A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 113 (2009), 438–446, 10.1182/blood-2008-04-150789.
198. Han, W., Zaynagetdinov, R., Yull, F.E., Polosukhin, V.V., Gleaves, L.A., Tanjore, H., et al. Molecular imaging of folate receptor beta-positive macrophages during acute lung inflammation. Am. J. Respir. Cell Mol. Biol. 53 (2015), 50–59, 10.1165/rcmb.2014-0289OC.
199. Furusho, Y., Miyata, M., Matsuyama, T., Nagai, T., Li, H., Akasaki, Y., et al. Novel therapy for atherosclerosis using recombinant immunotoxin against folate receptor beta-expressing macrophages. J. Am. Heart Assoc., 1, 2012, e003079, 10.1161/JAHA.112.003079.
200. Lin, Y., Wei, C., Liu, Y., Qiu, Y., Liu, C., Guo, F., Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis. Cancer Sci. 104 (2013), 1217–1225, 10.1111/cas.12202.
201. Corna, G., Campana, L., Pignatti, E., Castiglioni, A., Tagliafico, E., Bosurgi, L., et al. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 95 (2010), 1814–1822, 10.3324/haematol.2010.023879.
202. Wu, W., Luo, Y., Sun, C., Liu, Y., Kuo, P., Varga, J., et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 66 (2006), 970–980, 10.1158/0008-5472.CAN-05-2591.
203. Liu, Z., Xiong, M., Gong, J., Zhang, Y., Bai, N., Luo, Y., et al. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat. Commun., 5, 2014, 4280, 10.1038/ncomms5280.
204. Ruan, S., Hu, C., Tang, X., Cun, X., Xiao, W., Shi, K., et al. Increased gold nanoparticle retention in brain tumors by in situ enzyme-induced aggregation. ACS Nano 10 (2016), 10086–10098, 10.1021/acsnano.6b05070.
205. Choi, C.H.J., Alabi, C.A., Webster, P., Davis, M.E., Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 1235–1240, 10.1073/pnas.0914140107.
206. Clark, A.J., Davis, M.E., Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 12486–12491, 10.1073/pnas.1517048112.
207. Kang, T., Jiang, M., Jiang, D., Feng, X., Yao, J., Song, Q., et al. Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol. Pharm. 12 (2015), 2947–2961, 10.1021/acs.molpharmaceut.5b00222.
208. Movahedi, K., Schoonooghe, S., Laoui, D., Houbracken, I., Waelput, W., Breckpot, K., et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 72 (2012), 4165–4177, 10.1158/0008-5472.CAN-11-2994.
209. Cieslewicz, M., Tang, J., Yu, J.L., Cao, H., Zavaljevski, M., Motoyama, K., et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 15919–15924, 10.1073/pnas.1312197110.
210. Ngambenjawong, C., Gustafson, H.H., Pineda, J.M., Kacherovsky, N.A., Cieslewicz, M., Pun, S.H., Serum stability and affinity optimization of an M2 macrophage-targeting peptide (M2pep). Theranostics 6 (2016), 1403–1414, 10.7150/thno.15394.
211. Ngambenjawong, C., Pineda, J.M.B., Pun, S.H., Engineering an affinity-enhanced peptide through optimization of cyclization chemistry. Bioconjug. Chem. 27 (2016), 2854–2862, 10.1021/acs.bioconjchem.6b00502.
212. Ngambenjawong, C., Cieslewicz, M., Schellinger, J.G., Pun, S.H., Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. J. Control. Release 224 (2016), 103–111, 10.1016/j.jconrel.2015.12.057.
213. Lee, S., Kivimae, S., Dolor, A., Szoka, F.C., Macrophage-based cell therapies: the long and winding road. J. Control. Release 240 (2016), 527–540, 10.1016/j.jconrel.2016.07.018.
214. Choi, J., Kim, H.-Y., Ju, E.J., Jung, J., Park, J., Chung, H.-K., et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 33 (2012), 4195–4203, 10.1016/j.biomaterials.2012.02.022.
215. Madsen, S.J., Baek, S.-K., Makkouk, A.R., Krasieva, T., Hirschberg, H., Macrophages as cell-based delivery systems for nanoshells in photothermal therapy. Ann. Biomed. Eng. 40 (2012), 507–515, 10.1007/s10439-011-0415-1.
216. Ikehara, Y., Niwa, T., Biao, L., Ikehara, S.K., Ohashi, N., Kobayashi, T., et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res. 66 (2006), 8740–8748, 10.1158/0008-5472.CAN-06-0470.
217. Miller, M.A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat. Commun., 6, 2015, 8692, 10.1038/ncomms9692.
218. Dou, H., Destache, C.J., Morehead, J.R., Mosley, R.L., Boska, M.D., Kingsley, J., et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108 (2006), 2827–2835, 10.1182/blood-2006-03-012534.
219. Dou, H., Grotepas, C.B., McMillan, J.M., Destache, C.J., Chaubal, M., Werling, J., et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183 (2009), 661–669, 10.4049/jimmunol.0900274.
220. Zhao, Y., Haney, M.J., Klyachko, N.L., Li, S., Booth, S.L., Higginbotham, S.M., et al. Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. Nanomedicine (London) 6 (2011), 25–42, 10.2217/nnm.10.129.
221. Klyachko, N.L., Haney, M.J., Zhao, Y., Manickam, D.S., Mahajan, V., Suresh, P., et al. Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine (London) 9 (2014), 1403–1422, 10.2217/nnm.13.115.
222. Muthana, M., Kennerley, A.J., Hughes, R., Fagnano, E., Richardson, J., Paul, M., et al. Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nat. Commun., 6, 2015, 8009, 10.1038/ncomms9009.
223. Han, J., Zhen, J., Nguyen, V. Du, Go, G., Choi, Y., Ko, S.Y., et al. Hybrid-actuating macrophage-based microrobots for active cancer therapy. Sci. Rep., 6, 2016, 28717, 10.1038/srep28717.
224. Li, F., Ulrich, M., Jonas, M., Stone, I.J., Linares, G., Zhang, X., et al. Tumor associated macrophages can contribute to antitumor activity through FcgammaRmediated processing of antibody-drug conjugates. Mol. Cancer Ther., 2017, 10.1158/1535–7163.MCT-17-0019.
225. De Palma, M., Mazzieri, R., Politi, L.S., Pucci, F., Zonari, E., Sitia, G., et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14 (2008), 299–311, 10.1016/j.ccr.2008.09.004.
226. Pradel, L.P., Ooi, C.-H., Romagnoli, S., Cannarile, M.A., Sade, H., Ruttinger, D., et al. Macrophage susceptibility to Emactuzumab (RG7155) treatment. Mol. Cancer Ther. 15 (2016), 3077–3086, 10.1158/1535–7163.MCT-16-0157.
227. Carey, L.A., Winer, E.P., I-SPY 2 — toward more rapid progress in breast cancer treatment. N. Engl. J. Med. 375 (2016), 83–84, 10.1056/NEJMe1603691.